Using pharmacist-directed service improves quality of care for patients

Feb 08, 2011

DETROIT ¬– A Henry Ford Hospital study has found that a pharmacist-directed anticoagulation service improves the way medication is managed for patients with heparin-induced thrombocytopenia (HIT), a common but life-threatening thromboembolic disorder.

Researchers found that treated by the anticoagulation service had a favorable response to alternative anticoagulant drugs three times faster and were 32 percent more likely to receive proper dosage than patients who were treated with the same drugs by the patient's primary medical team.

This is the first time researchers evaluated the impact of the anticoagulation service on the efficiency and safety of using a different class of anticoagulant drugs called direct thrombin inhibitors for treating patients with HIT, in which a patient's platelet count drops after they receive the anticoagulant drug heparin.

The study is to be published online Tuesday at www.theannals.com in the February issue of The Annals of Pharmacotherapy.

"Based on our findings, we believe this type of service is a valuable strategy for improving the quality of care of patients with HIT," says James Kalus, PharmD, senior clinical pharmacy manager at Henry Ford and senior author of the study.

It is estimated that up to 3 percent of patients exposed to various forms of heparin may develop HIT, which is commonly treated in hospitalized patients. If a decrease in a patient's platelet count is not treated quickly and efficiently, serious blood clots can develop.

Henry Ford sought to evaluate whether a pharmacist-directed anticoagulation service could impact the care or outcomes of 193 HIT patients who were treated using direct thrombin inhibitors lepirudin or argatroban between 2005 and 2009. Ninety-eight patients were managed by the anticoagulation service and 95 patients were managed by the primary medical team.

Dr. Kalus says the study's findings "represent real improvements in quality of care."

"The pharmacist-directed anticoagulation service is a viable approach to standardize the use of direct thrombin inhibitors for improving both the efficiency and safety of these complicated medications in an inpatient setting," he says.

Explore further: Teva to lift bid for Mylan: report

Related Stories

Vancomycin is the drug of choice for treating cellulitis

Oct 23, 2010

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, ...

Belt and braces approach may prevent deep vein thromboses

Oct 08, 2008

Combining short periods of leg compression with medications such as heparin is more effective at preventing blood clots in high-risk patients than using either preventative measure alone. A team of Cochrane Researchers believe ...

Recommended for you

Teva to lift bid for Mylan: report

5 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

10 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.